Evidence map›Paper›PMID 28955941›Full record

ArticleBiochemistry and biophysics reports2016

Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy.

E Panayiotou, R Papacharalambous, A Antoniou, G Christophides, L Papageorgiou, E Fella, S Malas, T Kyriakides

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

E PanayiotouCyprus Institute of Neurology and Genetics, P.O.Box 23462, 1683 Nicosia, Cyprus.
R PapacharalambousCyprus Institute of Neurology and Genetics, P.O.Box 23462, 1683 Nicosia, Cyprus.
A AntoniouCyprus School of Molecular Medicine, P.O.Box 23462, 1683 Nicosia, Cyprus.
G ChristophidesCyprus School of Molecular Medicine, P.O.Box 23462, 1683 Nicosia, Cyprus.
L PapageorgiouCyprus School of Molecular Medicine, P.O.Box 23462, 1683 Nicosia, Cyprus.
E FellaCyprus School of Molecular Medicine, P.O.Box 23462, 1683 Nicosia, Cyprus.
S MalasCyprus Institute of Neurology and Genetics, P.O.Box 23462, 1683 Nicosia, Cyprus.
T KyriakidesCyprus Institute of Neurology and Genetics, P.O.Box 23462, 1683 Nicosia, Cyprus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Penetrance and age of onset of ATTRV30M amyloidotic neuropathy varies significantly among different populations. This variability has been attributed to both genetic and environmental modifiers. We studied the effect of genetic background on phenotype in two lines of transgenic mice bearing the same ATTRV30M transgene. Amyloid deposition, transthyretin (TTR), megalin, clusterin and disease markers of endoplasmic reticulum stress, the ubiquitin-proteasome system, apoptosis, and complement activation were assessed with WB and immunohistochemistry in donor and recipient tissue. Our results indicate that genetic background modulates amyloid deposition by influencing TTR handling in recipient tissue and may partly account for the marked variability in penetrance observed in various world populations.

Indexed as

AmyloidATTRV30MGenetic background

Identifiers

PMID28955941
PMCPMC5613746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.